Epigenome-Wide DNA Methylation Profiling of Matched Primary Breast Cancers and Brain Metastases Reveals Epigenetic Markers linked to Metastatic Progression: A Preliminary Study.
Beate Alinger-Scharinger, Georg Hutarew, Christoph Schwartz, Alexander Romagna, Ognian Kalev, Serge Weis, Simon P Gampenrieder, Gabriel Rinnerthaler, Vanessa Castagnaviz, Franz Gassner, Roland Geisberger, Nadja Zaborsky, Richard Greil, Karl Sotlar, Theo F J Kraus
{"title":"Epigenome-Wide DNA Methylation Profiling of Matched Primary Breast Cancers and Brain Metastases Reveals Epigenetic Markers linked to Metastatic Progression: A Preliminary Study.","authors":"Beate Alinger-Scharinger, Georg Hutarew, Christoph Schwartz, Alexander Romagna, Ognian Kalev, Serge Weis, Simon P Gampenrieder, Gabriel Rinnerthaler, Vanessa Castagnaviz, Franz Gassner, Roland Geisberger, Nadja Zaborsky, Richard Greil, Karl Sotlar, Theo F J Kraus","doi":"10.7150/ijms.130407","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer represents the most prevalent malignancy among women globally, with a rising incidence of metastases to the central nervous system. The presence of brain metastases is associated with a poor prognosis, largely due to the limited availability of effective treatment modalities.</p><p><strong>Methods: </strong>In this preliminary study, we performed an epigenome-wide DNA-methylation analysis of matched primary breast cancer and brain metastasis of the same patients applying the Illumina Infinium EPIC Bead Chip interrogating more than 850,000 CpG sites at single base resolution.</p><p><strong>Results: </strong>We found that primary breast cancers and corresponding metastases are very similar on the global DNA methylation level. Detailed analysis showed aberrant methylation patterns that reflect the process of brain metastasis. We identified 107 nominally significant methylated CpG sites (DMCGs) within promoter and gene regions (Δβ ≥ 0.1, <i>p</i>-value < 0.05), when comparing primary breast tumors to their brain metastatic counterparts. However, due to the limited sample size, no individual CpG site retained statistically significant after correction for multiple testing.</p><p><strong>Conclusion: </strong>Our study highlights specific aberrant DNA methylation patterns that are associated with brain metastasis in breast cancer. Characterizing these epigenetic alterations provides a promising avenue for identifying novel therapeutic targets and clinically relevant biomarkers.</p>","PeriodicalId":14031,"journal":{"name":"International Journal of Medical Sciences","volume":"23 11","pages":"3554-3564"},"PeriodicalIF":3.7000,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685463/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/ijms.130407","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Breast cancer represents the most prevalent malignancy among women globally, with a rising incidence of metastases to the central nervous system. The presence of brain metastases is associated with a poor prognosis, largely due to the limited availability of effective treatment modalities.
Methods: In this preliminary study, we performed an epigenome-wide DNA-methylation analysis of matched primary breast cancer and brain metastasis of the same patients applying the Illumina Infinium EPIC Bead Chip interrogating more than 850,000 CpG sites at single base resolution.
Results: We found that primary breast cancers and corresponding metastases are very similar on the global DNA methylation level. Detailed analysis showed aberrant methylation patterns that reflect the process of brain metastasis. We identified 107 nominally significant methylated CpG sites (DMCGs) within promoter and gene regions (Δβ ≥ 0.1, p-value < 0.05), when comparing primary breast tumors to their brain metastatic counterparts. However, due to the limited sample size, no individual CpG site retained statistically significant after correction for multiple testing.
Conclusion: Our study highlights specific aberrant DNA methylation patterns that are associated with brain metastasis in breast cancer. Characterizing these epigenetic alterations provides a promising avenue for identifying novel therapeutic targets and clinically relevant biomarkers.
期刊介绍:
Original research papers, reviews, and short research communications in any medical related area can be submitted to the Journal on the understanding that the work has not been published previously in whole or part and is not under consideration for publication elsewhere. Manuscripts in basic science and clinical medicine are both considered. There is no restriction on the length of research papers and reviews, although authors are encouraged to be concise. Short research communication is limited to be under 2500 words.